Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Research on the value of the T cell spot test for tuberculosis for the diagnosis of lungcancer combined with pulmonary tuberculosis 30079988 2018 11 14 1759-7714 9 10 2018 Oct Thoracic cancer Thorac Cancer Research on the value of the T cell spot test for tuberculosis for the diagnosis of lungcancer combined with pulmonary tuberculosis. 1231-1234 10.1111/1759-7714.12816 This study was conducted to investigate the value of the T cell spot test for tuberculosis (T-SPOT.TB) for the diagnosis (...) of patients with lungcancer combined with pulmonary tuberculosis (LCTB). Thirty-six patients diagnosed with LCTB who received treatment at Shandong Provincial Chest Hospital from September 2014 to 2017 were randomly chosen and enrolled as an observation group; 63 patients diagnosed with LC alone in the same period were included as the control. The T-SPOT.TB results of the two groups were compared. The positive rate of T-SPOT.TB in 36 patients with LCTB was 88.9% (32/36), and in 63 patients with LC
Surgically treated lungcancer patients: do they all smoke and would they all have been detected with lungcancer screening? 30083553 2018 11 14 2312-0541 4 3 2018 Jul ERJ open research ERJ Open Res Surgically treated lungcancer patients: do they all smoke and would they all have been detected with lungcancer screening? 00001-2018 10.1183/23120541.00001-2018 Since publication of the National LungCancer Screening Trial (NLST) results early lungcancer detection has been widely studied (...) , targeting individuals based on smoking history and age. However, over recent decades several changes in lungcancer epidemiology, including risk factors, have taken place. The aim of the current study was to explore smoking prevalence among lungcancer patients who had been treated surgically or undergone a diagnostic operation and whether these patients would have met the NLST inclusion criteria. All patients operated on for lungcancer in a university hospital in Estonia between 2009 and 2015 were
Correlation between radiomic features based on contrastâ€enhanced computed tomography images and Kiâ€67 proliferation index in lungcancer: A preliminary study 30070037 2018 11 14 1759-7714 9 10 2018 Oct Thoracic cancer Thorac Cancer Correlation between radiomic features based on contrast-enhanced computed tomography images and Ki-67 proliferation index in lungcancer: A preliminary study. 1235-1240 10.1111/1759-7714.12821 The purpose of the study was to investigate the association between (...) radiomic features based on contrast-enhanced multidetector computed tomography (CT) and the Ki-67 proliferation index (PI) in patients with lungcancer. One hundred and ten patients with lungcancer confirmed by surgical histology were retrospectively included. Radiomic features were extracted from preoperative contrast-enhanced chest multidetector CT images for each tumor using open-source three-dimensional Slicer software. Statistical analysis was performed to determine significant radiomic features
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell LungCancer: A Randomized Phase III NVALT-11/DLCRG-02 Study 29787357 2018 08 07 1527-7755 36 23 2018 Aug 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell LungCancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. 2366-2377 10.1200/JCO (...) .2017.77.5817 Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lungcancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging-were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell LungCancer 29768118 2018 07 27 1527-7755 36 22 2018 Aug 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell LungCancer. 2251-2258 10.1200/JCO.2017.77.4794 Purpose (...) The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lungcancer. Here, we report the final overall survival (OS) results. Patients and Methods Patients were randomly assigned to receive oral crizotinib 250 mg twice daily (n = 172) or intravenous pemetrexed 500 mg/m 2 plus cisplatin 75 mg/m 2 or carboplatin (area under the concentration-time curve of 5 to 6 mg·mL/min
Lungcancer Top results for lungcancer - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lungcancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical
Incorporating Coexisting Chronic Illness into LungCancer Screening: A Research Statement AMERICANTHORACICSOCIETY DOCUMENTS IncorporatingCoexisting ChronicIllness into Decisionsabout Patient Selection for LungCancer Screening An Of?cial American Thoracic Society Research Statement M. Patricia Rivera, Nichole T. Tanner, Gerard A. Silvestri, Frank C. Detterbeck, Martin C. Tammem¨ agi, Robert P. Young, Christopher G. Slatore, Tanner J. Caverly, Cynthia M. Boyd, Dejana Braithwaite, Joelle T. Fathi (...) -makingwithpatientswhomaynot bene?tfromLCSowingtocoexistingchronicillness.Thisstatement establishesaresearchframeworktoaddressessentialquestions regarding how toincorporateand communicaterisks of comorbiditiesintopatientselectionanddecisionsregardingLCS. Keywords: lungcancer screening; comorbidities; communication of risk Contents Overview Key Conclusions and Recommendations Introduction Methods Results Juxtaposing LungCancer Risk and Competing Risk of Death from Other Causes COPD, LungCancer Risk, Competing Risk
Alectinib hydrochloride (Alecensa) - anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC) 1 alectinib 150mg hard capsules (Alecensa ® ) SMC2012 Roche Products Limited 6 July 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under (...) the orphan medicine process alectinib (Alecensa ® ) is accepted for use within NHS Scotland. Indication under review: as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC). Alectinib, compared with another tyrosine kinase inhibitor, significantly improved progression-free survival in treatment-naïve adults with advanced or recurrent ALK-positive NSCLC. This SMC advice takes account of the benefits
Tobacco Dependence Predicts Higher LungCancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial 29793736 2018 07 25 1931-3543 154 1 2018 Jul Chest Chest Tobacco Dependence Predicts Higher LungCancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. 110-118 S0012-3692(18)30587-7 10.1016/j.chest.2018.04.016 Incorporating tobacco treatment within lungcancer screening programs has the potential to influence (...) performed. Clinical outcomes (smoking cessation, lungcancer, and mortality) were assessed with descriptive statistics and χ 2 tests stratified according to nicotine dependence. Logistic and Cox regression models were used to study the influence of dependence on smoking cessation and mortality, respectively. Patients with high dependence scores were less likely to quit smoking compared with low dependence smokers (TTFC OR, 0.50 [95% CI, 0.42-0.60]). Indicators of high dependence, as measured according
Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with earlyâ€stage nonâ€small cell lungcancer 30047626 2018 11 14 1759-7714 9 9 2018 Sep Thoracic cancer Thorac Cancer Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lungcancer. 1136-1144 10.1111/1759-7714.12797 S100A13 plays a key role in tumor growth and metastasis. The purpose of this study (...) was to investigate the prognostic significance of S100A13 expression, microvessel density (MVD), and survival in early stage non-small cell lungcancer (NSCLC). In silico analysis was performed to determine the associations between S100A13 and NSCLC. The data of 82 patients with early-stage NSCLC who underwent radical resection were evaluated. Paraffin-embedded tumor specimens were stained with S100A13 and CD31 (a specific endothelial marker) using immunohistochemical methods. Prognostic significance
Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Nonâ€“Small-Cell LungCancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution 30085881 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non-Small-Cell LungCancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution. 1-8 10.1200/JGO.18.00020 Purpose Stereotactic body radiation therapy (SBRT (...) ) has emerged as a treatment option for patients with non-small-cell lungcancer (NSCLC). We report the clinical outcomes and toxicity for patients with inoperable primary NSCLC treated with SBRT. Methods Between 2007 and 2015, 102 consecutive lung lesions were treated with SBRT at our center, of which 59 primary NSCLC lesions (from 54 patients with inoperable disease) were retrospectively reviewed (43 lesions were excluded because of metastases or because there was no biopsy specimen). We report
Low-dose nivolumab can be effective in non-small cell lungcancer: alternative option for financial toxicity 30094065 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Low-dose nivolumab can be effective in non-small cell lungcancer: alternative option for financial toxicity. e000332 10.1136/esmoopen-2018-000332 Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose-response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose (...) nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cell lungcancer (NSCLC). Outcomes of patients with NSCLC treated with nivolumab as a routine practice at two tertiary hospitals in Korea were retrospectively analysed. Patients who could not afford standard nivolumab treatment received low-dose nivolumab (20 or 100 mg fixed dose every 3 weeks). Others received standard dose of 3 mg/kg every 2 weeks. Progression-free survival (PFS) and overall
CSF-1 and Ang-2 serum levels â€” prognostic and diagnostic partners in non-small cell lungcancer 30094067 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open CSF-1 and Ang-2 serum levels - prognostic and diagnostic partners in non-small cell lungcancer. e000349 10.1136/esmoopen-2018-000349 Lungcancer is the most incident and lethal form of cancer, with late diagnosis as a major determinant of its bad prognosis. Immunotherapies targeting immune checkpoints improve survival, but positive results (...) encompass only 30%-40% of the patients, possibly due to alternative pathways to immunosuppression, including tumour-associated macrophages (TAM). Colony stimulating factor-1 (CSF-1) is implicated in TAM differentiation and recruitment to tumours and in tumour angiogenesis, through a special setting of Tie-2-expressing macrophages, which respond to angiopoietin-2 (Ang-2). We evaluated the role of serum levels of CSF-1 in non-small cell lungcancer (NSCLC) prognosis and whether these could serve
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lungcancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lungcancer) 30094074 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lungcancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin (...) in Lungcancer). e000394 10.1136/esmoopen-2018-000394 This single-arm phase II trial aimed to evaluate a stop-and-go strategy with cisplatin-based chemotherapy and bevacizumab in advanced non-squamous non-small cell lungcancer (NSCLC). Patients were initially treated with three cycles of pemetrexed, cisplatin plus bevacizumab (sequence 1) followed by bevacizumab maintenance and after progression, re-introduction of three cycles of pemetrexed, cisplatin plus bevacizumab (sequence 2) and pemetrexed
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lungcancer 30018815 2018 11 14 2059-7029 3 5 2018 ESMO open ESMO Open Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK -positive, crizotinib-resistant, non-small cell lungcancer. e000364 10.1136/esmoopen-2018-000364 In a phase II North American study (NP28761; NCT01871805), the anaplastic lymphoma kinase (...) (ALK) inhibitor alectinib demonstrated both systemic and central nervous system (CNS) efficacy with good tolerability in patients with ALK -positive non-small cell lungcancer. We describe patient-reported outcomes (PROs) from the NP28761 study. PROs and health-related quality of life (HRQoL) benefits were assessed using two self-administered questionnaires (the European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire-Core (EORTC QLQ-C30), and the 13-item